Ironwood Pharmaceuticals Inc (IRWD) is a Healthcare · Drug Manufacturers - Specialty & Generic company listed on NASDAQ. Price $4.35 (+2.84%), Market cap $0.65B, P/E ratio 6.32, 52-week low–high $0.57 ~ $5.39.
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a syn
Financial statements, price targets, institutional (13F) holdings and related news for Ironwood Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Ironwood Pharmaceuticals Inc trades at $4.35 (+2.84%). Real-time quotes and charts are available on BlackAll Trade.
Ironwood Pharmaceuticals Inc has a market cap of about $0.65B. Its P/E ratio is 6.32.
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationa